The effects of nanocurcumin on Treg cell responses and treatment of ankylosing spondylitis patients: A randomized, double‐blind, placebo‐controlled clinical trial
Journal of Cellular Biochemistry2019Vol. 121(1), pp. 103–110
Citations Over TimeTop 10% of 2019 papers
Majid Ahmadi, Mehrzad Hajialilo, Sanam Dolati, Shadi Eghbal‐Fard, Hanieh Heydarlou, Mahnaz Ghaebi, Arezou Ghassembaglou, Leili Aghebati‐Maleki, Hossein Samadi Kafil, Amin Kamrani, Badrossadat Rahnama, Reza Rikhtegar, Mehdi Yousefi
Abstract
The findings suggested that dysregulation of Treg cells in PB influences the AS development and nanocurcumin therapy could regulate the Treg cells, and so could be useful in the treatment of AS and may be other autoimmune diseases. This study is registered with IRCT.ir, number IRCT2017052927520N7.
Related Papers
- → Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS‐G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ‐S)(2011)355 cited
- → High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers(2007)3 cited
- → Case report: Tracheobronchomegaly in association with ankylosing spondylitis(1991)14 cited
- [Sex influence on the cardiac complication of ankylosing spondylitis--analysis of 95 cases of ankylosing spondylitis including our case].(1990)
- Expression and clinical value of platelet in activity ankylosing spondylitis(2012)